Enpatoran, a TLR7/8 inhibitor, demonstrated clinically meaningful improvements in disease activity among patients with ...

Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025 ...

The Johns Hopkins Department of Dermatology is conducting a research study led by Dr. Jun Kang to better understand the cellular mechanisms driving disease activity and long-term skin damage in ...

There are multiple types of lupus, with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) being two primary forms. Symptoms can range from mild to life-threatening, ...

EMD Serono Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025 Business Wire Thu, Jun 12, 2025, 5:30 AM 8 min read ...

Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...

Cohort A focused on patients with CLE or SLE with active lupus rash and evaluated organ-specific disease activity using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity ...

The study features a unique design across two lupus cohorts, including both patients with active SLE and cutaneous lupus erythematosus (CLE).